GB0000313D0 - Formulation - Google Patents

Formulation

Info

Publication number
GB0000313D0
GB0000313D0 GBGB0000313.7A GB0000313A GB0000313D0 GB 0000313 D0 GB0000313 D0 GB 0000313D0 GB 0000313 A GB0000313 A GB 0000313A GB 0000313 D0 GB0000313 D0 GB 0000313D0
Authority
GB
United Kingdom
Prior art keywords
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0000313.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0000313(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to GBGB0000313.7A priority Critical patent/GB0000313D0/en
Publication of GB0000313D0 publication Critical patent/GB0000313D0/en
Priority to GBGB0008837.7A priority patent/GB0008837D0/en
Priority to SK984-2002A priority patent/SK287221B6/sk
Priority to BRPI0107445-8A priority patent/BR0107445B1/pt
Priority to DK01900186.6T priority patent/DK1250138T4/en
Priority to CNB018035469A priority patent/CN1222292C/zh
Priority to HU0204137A priority patent/HU230162B1/hu
Priority to GB0100407A priority patent/GB2359254B/en
Priority to ES01900186.6T priority patent/ES2248272T5/es
Priority to PCT/GB2001/000049 priority patent/WO2001051056A1/en
Priority to HK03105241.3A priority patent/HK1052884B/zh
Priority to EG20010017A priority patent/EG24074A/xx
Priority to IL15023001A priority patent/IL150230A0/xx
Priority to SI200130446T priority patent/SI1250138T2/sl
Priority to EP05016921A priority patent/EP1669073A3/en
Priority to EP10180667.7A priority patent/EP2266573B1/en
Priority to HK03101532.0A priority patent/HK1049286B/en
Priority to PL356030A priority patent/PL202525B1/pl
Priority to JP2001551480A priority patent/JP3713237B2/ja
Priority to EP01900186.6A priority patent/EP1250138B2/en
Priority to DK10180667.7T priority patent/DK2266573T3/en
Priority to KR1020027008855A priority patent/KR100802366B1/ko
Priority to MXPA02006698A priority patent/MXPA02006698A/es
Priority to EP10180661.0A priority patent/EP2286818B1/en
Priority to US10/169,777 priority patent/US20030125387A1/en
Priority to PT101806677T priority patent/PT2266573E/pt
Priority to ES10180667.7T priority patent/ES2543384T3/es
Priority to RU2002121507A priority patent/RU2263507C9/ru
Priority to AT01900186T priority patent/ATE306928T1/de
Priority to EEP200200387A priority patent/EE05421B1/xx
Priority to AU23863/01A priority patent/AU762080B2/en
Priority to DE60114145.8T priority patent/DE60114145T3/de
Priority to SI200131044T priority patent/SI2266573T1/sl
Priority to CZ2002-2384A priority patent/CZ304689B6/cs
Priority to CA002351004A priority patent/CA2351004C/en
Priority to BE2001/0021A priority patent/BE1013477A3/fr
Priority to PT102548A priority patent/PT102548A/pt
Priority to IT000005A priority patent/ITTO20010005A1/it
Priority to US09/756,291 priority patent/US6774122B2/en
Priority to MYPI20010107A priority patent/MY118583A/en
Priority to TW090100514A priority patent/TWI259086B/zh
Priority to DE10100779A priority patent/DE10100779A1/de
Priority to CO01001317A priority patent/CO5280206A1/es
Priority to FR0100248A priority patent/FR2803516B1/fr
Priority to IT2001TO000008A priority patent/ITTO20010008A1/it
Priority to ES200100057A priority patent/ES2186517B2/es
Priority to CH00029/01A priority patent/CH696260A5/de
Priority to ARP010100100A priority patent/AR027510A1/es
Priority to NL1017075A priority patent/NL1017075C2/nl
Priority to UA2002086628A priority patent/UA75879C2/uk
Priority to ZA200204165A priority patent/ZA200204165B/xx
Priority to IL150230A priority patent/IL150230A/en
Priority to BG106833A priority patent/BG65776B1/bg
Priority to IS6454A priority patent/IS2932B/is
Priority to NO20023227A priority patent/NO336286B1/no
Priority to JP2003362875A priority patent/JP2004107353A/ja
Priority to US10/872,784 priority patent/US7456160B2/en
Priority to US12/285,887 priority patent/US8329680B2/en
Priority to HK11103860.8A priority patent/HK1150021B/en
Priority to JP2011135962A priority patent/JP2011190275A/ja
Priority to US13/602,667 priority patent/US8466139B2/en
Priority to NO20150741A priority patent/NO337329B1/no
Priority to CY20151100648T priority patent/CY1116520T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0000313.7A 2000-01-10 2000-01-10 Formulation Ceased GB0000313D0 (en)

Priority Applications (63)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
SK984-2002A SK287221B6 (sk) 2000-01-10 2001-01-08 Farmaceutická formulácia obsahujúca fulvestrant
BRPI0107445-8A BR0107445B1 (pt) 2000-01-10 2001-01-08 formulação farmacêutica, e, uso de fulvestrante na preparação de uma formulação farmacêutica.
DK01900186.6T DK1250138T4 (en) 2000-01-10 2001-01-08 Fulvestrantformulering
CNB018035469A CN1222292C (zh) 2000-01-10 2001-01-08 氟维司群制剂
HU0204137A HU230162B1 (hu) 2000-01-10 2001-01-08 Fulvesztrantot tartalmazó gyógyászati készítmény
GB0100407A GB2359254B (en) 2000-01-10 2001-01-08 Formulation
ES01900186.6T ES2248272T5 (es) 2000-01-10 2001-01-08 Formulación de fulvestrant
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
HK03105241.3A HK1052884B (zh) 2000-01-10 2001-01-08 氟维司群制剂
EG20010017A EG24074A (en) 2000-01-10 2001-01-08 Formulation
IL15023001A IL150230A0 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
SI200130446T SI1250138T2 (sl) 2000-01-10 2001-01-08 Formulacije fulvestranta
EP05016921A EP1669073A3 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
EP10180667.7A EP2266573B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
HK03101532.0A HK1049286B (en) 2000-01-10 2001-01-08 Fulvestrant formulation
PL356030A PL202525B1 (pl) 2000-01-10 2001-01-08 Preparat farmaceutyczny fulwestrantu
JP2001551480A JP3713237B2 (ja) 2000-01-10 2001-01-08 フルベストラント製剤
EP01900186.6A EP1250138B2 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
DK10180667.7T DK2266573T3 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
KR1020027008855A KR100802366B1 (ko) 2000-01-10 2001-01-08 풀베스트란트 제제
MXPA02006698A MXPA02006698A (es) 2000-01-10 2001-01-08 Formulacion de fulvestrant.
EP10180661.0A EP2286818B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
US10/169,777 US20030125387A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
PT101806677T PT2266573E (pt) 2000-01-10 2001-01-08 Formulação de fulvestrant
ES10180667.7T ES2543384T3 (es) 2000-01-10 2001-01-08 Formulación de fulvestrant
RU2002121507A RU2263507C9 (ru) 2000-01-10 2001-01-08 Композиция фульвестранта
AT01900186T ATE306928T1 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung
EEP200200387A EE05421B1 (et) 2000-01-10 2001-01-08 Fulvestrandi formulatsioonid
AU23863/01A AU762080B2 (en) 2000-01-10 2001-01-08 Fulvestrant formulation
DE60114145.8T DE60114145T3 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung
SI200131044T SI2266573T1 (sl) 2000-01-10 2001-01-08 Formulacija fulvestranta
CZ2002-2384A CZ304689B6 (cs) 2000-01-10 2001-01-08 Farmaceutický přípravek obsahující fulvestrant a jeho použití pro výrobu léčiva
CA002351004A CA2351004C (en) 2000-01-10 2001-01-08 Formulation
BE2001/0021A BE1013477A3 (fr) 2000-01-10 2001-01-09 Formulation.
PT102548A PT102548A (pt) 2000-01-10 2001-01-09 Formulacao farmaceutica para administracao por injeccao do composto 7alfa-¬9-(4,4,5,5,5-pentafluoropentilsulfinil)-nonil| estra-1,3,5(10)-trieno-3,17beta-diol (fulvestrant)
IT000005A ITTO20010005A1 (it) 2000-01-10 2001-01-09 Formulazione farmaceutica.
US09/756,291 US6774122B2 (en) 2000-01-10 2001-01-09 Formulation
MYPI20010107A MY118583A (en) 2000-01-10 2001-01-10 Formulation
TW090100514A TWI259086B (en) 2000-01-10 2001-01-10 Pharmaceutical formulation adapted for intra-muscular injection
DE10100779A DE10100779A1 (de) 2000-01-10 2001-01-10 Formulierung
CO01001317A CO5280206A1 (es) 2000-01-10 2001-01-10 Formulacion farmaceutica de liberacion sostenida adaptada para administracion por inyeccion
FR0100248A FR2803516B1 (fr) 2000-01-10 2001-01-10 Formulation injectable de fulvestrant
IT2001TO000008A ITTO20010008A1 (it) 2000-01-10 2001-01-10 Formulazione farmaceutica
ES200100057A ES2186517B2 (es) 2000-01-10 2001-01-10 Formulacion farmaceutica que contiene fulvestrant.
CH00029/01A CH696260A5 (de) 2000-01-10 2001-01-10 Fulvestrant Formulierung.
ARP010100100A AR027510A1 (es) 2000-01-10 2001-01-10 Formulacion
NL1017075A NL1017075C2 (nl) 2000-01-10 2001-01-10 Preparaat.
UA2002086628A UA75879C2 (en) 2000-01-10 2001-08-01 Fulvestrant composition (variants)
ZA200204165A ZA200204165B (en) 2000-01-10 2002-05-24 Fulvestrant formulation.
IL150230A IL150230A (en) 2000-01-10 2002-06-13 Formulation of Fulvestrant
BG106833A BG65776B1 (bg) 2000-01-10 2002-06-18 Фулвестрантов състав
IS6454A IS2932B (is) 2000-01-10 2002-07-03 Fúlvestrant samsetning
NO20023227A NO336286B1 (no) 2000-01-10 2002-07-03 Fulvestrant-formulering og sprøyte eller glassbeholder inneholdende samme
JP2003362875A JP2004107353A (ja) 2000-01-10 2003-10-23 フルベストラント製剤
US10/872,784 US7456160B2 (en) 2000-01-10 2004-06-22 Formulation
US12/285,887 US8329680B2 (en) 2000-01-10 2008-10-15 Formulation
HK11103860.8A HK1150021B (en) 2000-01-10 2011-04-18 Fulvestrant formulation
JP2011135962A JP2011190275A (ja) 2000-01-10 2011-06-20 フルベストラント製剤
US13/602,667 US8466139B2 (en) 2000-01-10 2012-09-04 Formulation
NO20150741A NO337329B1 (no) 2000-01-10 2015-06-08 Anvendelse av fulvestrant-formulering for behandling av brystkreft
CY20151100648T CY1116520T1 (el) 2000-01-10 2015-07-22 Φαρμακοτεχνικη μορφη fulvestrant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (1)

Publication Number Publication Date
GB0000313D0 true GB0000313D0 (en) 2000-03-01

Family

ID=26243352

Family Applications (3)

Application Number Title Priority Date Filing Date
GBGB0000313.7A Ceased GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A Ceased GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0100407A Expired - Lifetime GB2359254B (en) 2000-01-10 2001-01-08 Formulation

Family Applications After (2)

Application Number Title Priority Date Filing Date
GBGB0008837.7A Ceased GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
GB0100407A Expired - Lifetime GB2359254B (en) 2000-01-10 2001-01-08 Formulation

Country Status (41)

Country Link
US (5) US20030125387A1 (enExample)
EP (4) EP1669073A3 (enExample)
JP (3) JP3713237B2 (enExample)
KR (1) KR100802366B1 (enExample)
CN (1) CN1222292C (enExample)
AR (1) AR027510A1 (enExample)
AT (1) ATE306928T1 (enExample)
AU (1) AU762080B2 (enExample)
BE (1) BE1013477A3 (enExample)
BG (1) BG65776B1 (enExample)
BR (1) BR0107445B1 (enExample)
CA (1) CA2351004C (enExample)
CH (1) CH696260A5 (enExample)
CO (1) CO5280206A1 (enExample)
CY (1) CY1116520T1 (enExample)
CZ (1) CZ304689B6 (enExample)
DE (2) DE60114145T3 (enExample)
DK (2) DK1250138T4 (enExample)
EE (1) EE05421B1 (enExample)
EG (1) EG24074A (enExample)
ES (3) ES2248272T5 (enExample)
FR (1) FR2803516B1 (enExample)
GB (3) GB0000313D0 (enExample)
HK (2) HK1052884B (enExample)
HU (1) HU230162B1 (enExample)
IL (2) IL150230A0 (enExample)
IS (1) IS2932B (enExample)
IT (2) ITTO20010005A1 (enExample)
MX (1) MXPA02006698A (enExample)
MY (1) MY118583A (enExample)
NL (1) NL1017075C2 (enExample)
NO (2) NO336286B1 (enExample)
PL (1) PL202525B1 (enExample)
PT (2) PT2266573E (enExample)
RU (1) RU2263507C9 (enExample)
SI (2) SI2266573T1 (enExample)
SK (1) SK287221B6 (enExample)
TW (1) TWI259086B (enExample)
UA (1) UA75879C2 (enExample)
WO (1) WO2001051056A1 (enExample)
ZA (1) ZA200204165B (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
EP1406662A1 (en) * 2001-07-07 2004-04-14 AstraZeneca AB Pharmaceutical formulation for the intramuscular administration of fulvestrant
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
SG165404A1 (en) * 2005-09-26 2010-10-28 Hospira Australia Pty Ltd Fulvestrant formulation
RU2338538C1 (ru) * 2007-02-09 2008-11-20 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Антигипотензивное средство
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2811258C (en) * 2010-09-16 2019-10-15 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
CA2836831C (en) * 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CA2869377C (en) * 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US20160060288A1 (en) 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
CN108430454A (zh) 2015-10-13 2018-08-21 西弥斯医疗有限公司 氟维司群组合物
DK3386500T3 (da) 2015-12-09 2022-12-12 Univ Illinois Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3441073B1 (en) 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
EP3440067B1 (en) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN109152785B (zh) 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
CN109843882A (zh) 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
BR112020009141A2 (pt) * 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
WO2019151353A1 (ja) * 2018-01-31 2019-08-08 富士フイルム株式会社 注射用製剤の製造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
JP7384903B2 (ja) 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
EP3873462A4 (en) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. CANCER TREATMENT METHODS IN BIOMARKER-IDENTIFIED PATIENTS WITH NON-COVALENT INHIBITORS OF CYCLINE-DEPENDENT KINASE 7 (CDK7)
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
EP4074304A4 (en) 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2023006010A (es) 2020-11-24 2023-06-08 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos.
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4525925A1 (en) 2022-05-20 2025-03-26 Novartis AG Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN119562832A (zh) 2022-05-20 2025-03-04 诺华股份有限公司 Met bcl-xl抑制剂抗体-药物缀合物及其使用方法
EP4676540A1 (en) 2023-03-10 2026-01-14 Novartis AG Panras inhibitor antibody-drug conjugates and methods of use thereof
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (enExample) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
NL7711916A (nl) * 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
ATE249206T1 (de) 1997-12-03 2003-09-15 Merck & Co Inc Langwirkende, injizierbare, formulierungen enthaltend rizinusöl
EP1169021B1 (en) 1999-04-01 2009-09-16 Hana Biosciences, Inc. Compositions and methods for treating lymphoma
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
EP1406662A1 (en) 2001-07-07 2004-04-14 AstraZeneca AB Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
CZ304689B6 (cs) 2014-09-03
NO20023227D0 (no) 2002-07-03
DK2266573T3 (en) 2015-07-20
ES2186517A1 (es) 2003-05-01
RU2263507C9 (ru) 2020-07-28
AR027510A1 (es) 2003-04-02
HK1049286A1 (en) 2003-05-09
NL1017075C2 (nl) 2001-09-25
HK1052884B (zh) 2006-07-14
GB2359254A (en) 2001-08-22
US7456160B2 (en) 2008-11-25
US8466139B2 (en) 2013-06-18
CH696260A5 (de) 2007-03-15
EP1669073A2 (en) 2006-06-14
CZ20022384A3 (cs) 2002-09-11
SK9842002A3 (en) 2003-05-02
NO336286B1 (no) 2015-07-13
JP3713237B2 (ja) 2005-11-09
PL202525B1 (pl) 2009-07-31
EP2286818A1 (en) 2011-02-23
CN1222292C (zh) 2005-10-12
EP1250138A1 (en) 2002-10-23
HK1049286B (en) 2006-04-07
BE1013477A3 (fr) 2002-02-05
DK1250138T3 (da) 2006-01-23
BR0107445B1 (pt) 2012-10-30
GB0008837D0 (en) 2000-05-31
ES2543384T3 (es) 2015-08-18
IL150230A0 (en) 2002-12-01
US20030125387A1 (en) 2003-07-03
GB2359254B (en) 2002-06-19
MXPA02006698A (es) 2002-09-30
MY118583A (en) 2004-12-31
CO5280206A1 (es) 2003-05-30
EP1250138B2 (en) 2015-07-08
IS2932B (is) 2015-12-15
HK1052884A1 (en) 2003-10-03
JP2003519659A (ja) 2003-06-24
PT2266573E (pt) 2015-07-28
EP1250138B1 (en) 2005-10-19
WO2001051056A1 (en) 2001-07-19
SI1250138T1 (sl) 2006-02-28
CY1116520T1 (el) 2017-03-15
HUP0204137A2 (hu) 2003-04-28
ITTO20010008A1 (it) 2002-07-10
ES2186517B2 (es) 2004-03-16
KR100802366B1 (ko) 2008-02-13
ES2248272T3 (es) 2006-03-16
IL150230A (en) 2006-10-31
JP2011190275A (ja) 2011-09-29
SK287221B6 (sk) 2010-03-08
NO20150741L (no) 2002-07-03
NO337329B1 (no) 2016-03-14
FR2803516B1 (fr) 2003-03-28
TWI259086B (en) 2006-08-01
US20050043285A1 (en) 2005-02-24
HK1150021A1 (en) 2011-10-28
CN1394141A (zh) 2003-01-29
ES2248272T5 (es) 2015-08-19
EP2266573A1 (en) 2010-12-29
UA75879C2 (en) 2006-06-15
EP2286818B1 (en) 2020-03-18
US20120329766A1 (en) 2012-12-27
EP2266573B1 (en) 2015-06-17
DE60114145D1 (de) 2006-03-02
RU2002121507A (ru) 2004-03-20
CA2351004C (en) 2003-02-18
AU2386301A (en) 2001-07-24
US20010020016A1 (en) 2001-09-06
DK1250138T4 (en) 2015-07-27
KR20020073499A (ko) 2002-09-26
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
ZA200204165B (en) 2003-10-29
GB0100407D0 (en) 2001-02-21
SI1250138T2 (sl) 2015-09-30
RU2263507C2 (ru) 2005-11-10
FR2803516A1 (fr) 2001-07-13
NO20023227L (no) 2002-07-03
DE10100779A1 (de) 2001-07-26
CA2351004A1 (en) 2001-07-10
ATE306928T1 (de) 2005-11-15
IS6454A (is) 2002-07-03
US20100152149A1 (en) 2010-06-17
ITTO20010005A1 (it) 2001-07-11
HUP0204137A3 (en) 2005-03-29
BG65776B1 (bg) 2009-11-30
US6774122B2 (en) 2004-08-10
JP2004107353A (ja) 2004-04-08
EE200200387A (et) 2003-10-15
BG106833A (en) 2003-03-31
EP1669073A3 (en) 2008-03-19
BR0107445A (pt) 2002-09-17
SI2266573T1 (sl) 2015-08-31
PT102548A (pt) 2001-07-31
EG24074A (en) 2008-05-11
NL1017075A1 (nl) 2001-07-11
US8329680B2 (en) 2012-12-11
HU230162B1 (hu) 2015-09-28
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
EE05421B1 (et) 2011-06-15
DE60114145T2 (de) 2006-07-13
PL356030A1 (en) 2004-06-14

Similar Documents

Publication Publication Date Title
EG24074A (en) Formulation
GB0000891D0 (en) Formulation
EG24226A (en) Formulation
GB0021303D0 (en) Use
GB0015490D0 (en) Novel formulations
GB0025788D0 (en) Use
GB9905898D0 (en) Controlled-dose formulation
GB9902304D0 (en) Formulation
IL154258A0 (en) Fungicidal formulation
GB0125492D0 (en) Formulation
GB9927614D0 (en) Sterliant formulation
GB0005070D0 (en) Use
GB0029634D0 (en) Use
GB2396812B (en) Formulation
GB2375048B (en) Formulation
GB0116619D0 (en) Formulation
GB0010846D0 (en) Formulation
GB0007112D0 (en) Formulation
GB0004124D0 (en) Formulation
GB0001144D0 (en) Glysophosate formulation
GB0023069D0 (en) Formulation
GB0112497D0 (en) Formulation
GB9902236D0 (en) Formulation
GB0004092D0 (en) Excerciser
GB0022027D0 (en) Disfectant formulations

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)